


Applicants' Agent. Applicants respectfully request that the following submissions be entered.

In respect of the required Information Disclosure Statements (IDS), Applicants enclose copies of the IDS filed with respect to the parent Patent Application 07/675,908 together with requisite fee of \$220.00 US to cover the cost of filing such IDS. In accordance with 1.98(d), the documents referred to therein are not included and can be examined in the prosecution file history of Parent Patent Application 07/675,908.

In respect of the objection to the disclosure due to informalities, Applicants enclose a single sided copy of the disclosure which includes the specification and claims on separate pages. No new matter has been added.

IN THE CLAIMS

Please amend the claims as follows:



11. (Amended) A method of treating a condition or disease in a mammal comprising administering to the mammal a therapeutically effective amount of an agent selected from the group consisting of a medicine and a therapeutic agent and combinations thereof [a medicinal and/or therapeutic agent] to treat the disease or condition and a sufficient amount of a form of hyaluronic acid selected from hyaluronic acid and its non-toxic salts and combinations thereof [and/or salts and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid thereof] sufficient to facilitate the penetration of the agent through the tissue [(including scar tissue)] at a [the] site to be treated through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg/70kg person.